What is XPOVIO?
XPOVIO, also known as selinexor, is a first-in-class oral selective inhibitor of nuclear export (SINE). XPOVIO is manufactured by Karyopharm Therapeutics.
The MMRF played a role in the development of XPOVIO, and the Multiple Myeloma Research Consortium (MMRC) is currently facilitating clinical trials evaluating its use in combination with other myeloma agents.
How is XPOVIO used?
XPOVIO is used in combination with dexamethasone (Sd) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior antimyeloma treatment regimens and are refractory to at least two proteasome inhibitors, at least two immunomodulatory drugs, and an anti-CD38 monoclonal antibody.
What types of patients can benefit from XPOVIO?
In a phase 2 clinical trial, XPOVIO (in combination with dexamethasone) was shown to be effective in:
How does XPOVIO work?
XPOVIO binds to and inhibits the nuclear export protein XPO1, leading to the accumulation of tumor-suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells while largely sparing normal cells.
How is XPOVIO administered?
XPOVIO is given orally at a dose of 80 mg along with dexamethasone (20 mg orally) twice a week (both drugs on days 1 and 3 of a 28-day cycle) until disease progression.
What are XPOVIO side effects?
The most common side effects seen in a clinical study with Sd included:
In this study, the most common serious side effects included:
What have XPOVIO clinical trials shown?
The approval of XPOVIO was based on results from the STORM trial, a phase 2 trial to determine the efficacy of XPOVIO combined with dexamethasone (Sd) in patients with RRMM.
How is XPOVIO currently being studied in myeloma?
XPOVIO is being evaluated in several clinical trials in the U.S.
Interested in learning more about XPOVIO clinical trials? Talk to an MMRF Nurse Patient Navigator to learn more or use our clinical trials finder:
Created July 2019
Please visit the sponsor’s official patient site for up-to-date information on XPOVIO.